中国生物制药(01177.HK) 公布,集团自主研发的“TQB3019 (BTK PROTAC)”已获得中国国家药品监督管理局的临床试验批准,拟用于治疗血液肿瘤。
TQB3019是基于集团OAPD技术平台开发的一款口服、靶向BTK的蛋白降解靶向嵌合体(PROTAC) 药物。目前,全球尚无同靶点PROTAC药物获批上市。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-09 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.